WallStSmart

American Tower Corp (AMT)vsLineage, Inc. Common Stock (LINE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

American Tower Corp generates 99% more annual revenue ($10.64B vs $5.36B). AMT leads profitability with a 23.8% profit margin vs -1.9%. AMT earns a higher WallStSmart Score of 62/100 (C+).

AMT

Buy

62

out of 100

Grade: C+

Growth: 4.0Profit: 8.5Value: 3.3Quality: 3.8
Piotroski: 4/9Altman Z: 0.33

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 5.0Quality: 3.8
Piotroski: 5/9Altman Z: 0.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMTSignificantly Overvalued (-390.6%)

Margin of Safety

-390.6%

Fair Value

$36.79

Current Price

$169.52

$132.73 premium

UndervaluedFair: $36.79Overvalued

Intrinsic value data unavailable for LINE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMT4 strengths · Avg: 9.3/10
Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Market CapQuality
$79.36B9/10

Large-cap with strong market position

Return on EquityProfitability
26.3%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
23.8%9/10

Keeps 24 of every $100 in revenue as profit

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

AMT4 concerns · Avg: 3.0/10
PEG RatioValuation
1.954/10

Expensive relative to growth rate

P/E RatioValuation
31.3x4/10

Premium valuation, high expectations priced in

Price/BookValuation
21.7x2/10

Trading at 21.7x book value

EPS GrowthGrowth
-33.2%2/10

Earnings declined 33.2%

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMT

The strongest argument for AMT centers on Operating Margin, Market Cap, Return on Equity. Profitability is solid with margins at 23.8% and operating margin at 44.9%.

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bear Case : AMT

The primary concerns for AMT are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

AMT profiles as a mature stock while LINE is a turnaround play — different risk/reward profiles.

AMT is growing revenue faster at 7.5% — sustainability is the question.

AMT generates stronger free cash flow (848M), providing more financial flexibility.

Monitor REIT - SPECIALTY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMT scores higher overall (62/100 vs 36/100), backed by strong 23.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Tower Corp

REAL ESTATE · REIT - SPECIALTY · USA

American Tower Corporation (also referred to as American Tower or ATC) is an American real estate investment trust and an owner and operator of wireless and broadcast communications infrastructure in several countries worldwide and is headquartered in Boston, Massachusetts.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.

Visit Website →

Want to dig deeper into these stocks?